ACAT2 and HMG-CoA reductase — Drug Target

All drugs that target ACAT2 and HMG-CoA reductase — marketed and clinical-stage. Includes 1 drug classes acting on this target.

Drug classes

ACAT2 inhibitor combined with statin

Phase 3 pipeline (1)

• Lapaquistat acetate and rosuvastatin · Takeda · ACAT2 inhibitor combined with statin · Cardiovascular
  Lapaquistat acetate inhibits ACAT2 (acyl-CoA:cholesterol acyltransferase 2) to reduce intestinal cholesterol absorption, while rosuvastatin inhibits HMG-CoA reductase to reduce hepatic cholesterol synthesis.